All Articles
Psychedelics

Big Pharma Is Making Another Move Into Psychedelic Drug Development

May 13, 2024
x min read
Big Pharma Is Making Another Move Into Psychedelic Drug Development

Pharmaceutical companies are getting ready for the next big disruption in drug development: psychedelics.

What’s happening:

  • Pharmaceutical giant AbbVie (NYSE: ABBV) has announced a new partnership with psychedelic drug developer Gilgamesh Pharmaceuticals to develop next generation psychedelic medicines for psychiatric disorders

By the numbers:

  • AbbVie will provide Gilgamesh with an upfront payment of $65M USD to begin research and development of potential new psychedelic compounds
  • Gilgamesh will have the opportunity to earn up to $1.95B USD through a combination of drug development milestones and future royalties

Going deeper:

  • The collaboration between AbbVie and Gilgamesh will focus on developing next generation psychedelics that do not induce psychoactive effects such as hallucinations that are common with first generation psychedelic compounds

The intrigue:

  • Gilgamesh was recently the recipient of a $14M USD grant from the National Institute on Drug Abuse for their novel ibogaine analogue for the treatment of opioid abuse

Discover the world's most disruptive early stage companies with 35,000+ investors.

The markets and trends that matter, made simple.

Join top talent at the world's most respected institutions, companies, and venture capital funds.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.